Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression

Journal of Endocrinological Investigation

Volumn 33, Issue 5, 2010, Pages 292-296

  Yao, X M ^a   Ye, S D ^a   Zai, Z ^b   Chen, Y ^b   Li, X C ^a   Yang, G W ^a   Wang, Y X ^c   Chen, K ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c Anhui Medical College   (China)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Matrix metalloproteinase 9; Simvastatin

Indexed keywords

ALBUMIN; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; RETINOL BINDING PROTEIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELECTRON MICROSCOPE; ENZYME REPRESSION; EPITHELIUM CELL; GLOMERULUS; GLUCOSE BLOOD LEVEL; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; URINARY EXCRETION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLOMERULAR BASEMENT MEMBRANE; HEMOGLOBIN A, GLYCOSYLATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LIPIDS; MALE; MATRIX METALLOPROTEINASE 9; MICROSCOPY, ELECTRON; ORGAN SIZE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN;

EID: 77954195454     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6558     Document Type: Article

References (22)

1. Osterby R, Gundersen HJ, Nyberg G, Aurell M. Advanced diabetic glomerulopathy. Quantitative structural characterization of nonoccluded glomeruli. Diabetes 1987, 36: 612-9.
2. Zhou X, Zhao X, Zhao Z. The relation between matrix metalloproteinase-9 expression in peripheral blood monocytes from patients with diabetic mellitus and development of microalbuminuria. Acta Academiae Medicinae Qingdao Universitatis 2001, 37: 274-6.
3. Amemiya T, Sasamura H, Mifune M, et al. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney lnt 1999, 56: 2055-63.
4. Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001, 495:159-66.
5. Wolffenbuttel BH, Franken AA, Vincent HH; Dutch Corail Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005, 257: 531-9.
6. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003,18: 265-72.
7. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003, 46: 843-51.
8. Gu L, Ni Z, Qian J, Tomino Y. Pravastatin inhibits carboxymethyllysine- induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron Exp Nephrol 2007,106: e1-10. (Pubitemid 46701515)
9. Nogaki F, Muso E, Yashiro M, et al. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells. Kidney lnt Suppl 1999, 71: S198-201. (Pubitemid 29304851)
10. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004, 89: 740-7.
11. Kunieda Y, Nakagawa K, Nishimura H, et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin Il in cultured rat aortic endothelial cells. Thromb Res 2003, 110: 227-34.
12. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages. Cardiovasc Pharmacol 2001, 37: 762-8.
13. Wassmann S, Laufs U, Bäumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin ll-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. MoI Pharmacol 2001, 59: 646-54.
14. McLennan SV, Kelly DJ, Cox AJ, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002, 45: 268-75.
15. Dong FQ, Li H, Cai WM, et al. Effect of pioglitazone on expressions of matrix metalloproteinase 2 and 9 in kidney of diabetic rats. Chin J Endocrinol Metab 2004, 20: 459-60.
16. Tashiro K, Koyanagi I, Ohara I, et al. Levels of urinary matrix metalloproteinase-9 (MMP - 9) and renal injuries in patients with type 2 diabetic nephropathy. J of Clin Lab Anal 2004, 18: 206-10.
17. Koh KK, Son JW, Ahn JY, et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemia while eating a step-II diet. Coron Artery Dis 2001,12: 305-11.
18. Nomura S, Yoshimura K, Akiyama N, et al. HMG-CoA reductase inhibitors reduce Matrix metalloproteinase-9 activity in human varicose veins. Eur Surg Res 2005, 37: 370-8.
19. Ichihara S, Noda A, Nagata K, et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 2006, 69: 726-35.
20. Aragno M, Mastrocola R, Medana C, et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 2006,147: 5967-74 (Pubitemid 44833515)
21. Laws PE, Spark JI, Cowled PA, Fitridge RA. The role of statins in vascular disease. Eur J Vase Endovasc Surg 2004, 27: 6-16.
22. ChenZ, Lei, Zhu L, Zhang J. Effects of simvastatin on TGF-beta system of diabetic rat kidneys. J Cent South Univ (Med Sci) 2005, 30: 593-6. (Pubitemid 41695854)